2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5900 5T4 marks leukemia stem cell-enriched compartments across myeloid malignancies and is selectively targeted by optimized CAR T cells

Muharrem Muftuoglu, MD, Li Li, MD, PhD2, Mahesh Basyal, BSc3, Sophia Vera German Kavle4, Michael Andreeff, MD, PhD5
1 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Acute myeloid leukemia (AML) is genetically, phenotypically, and clinically heterogeneous. Co-occurring mutations and clonal evolution generate hierarchies of leukemia stem cell (LSC)-like, progenitor/myeloid, monocytic, and erythroid-like states with distinct surface-antigen profiles. The resulting antigenic diversity is a major barrier to effective antigen-directed therapy. Established AML targets (e.g. CD33, CLL1, CD123) remain limited by incomplete leukemic coverage and overlap with normal hematopoietic compartments. Two complementary strategies may overcome these barriers: identifying antigens shared by bulk AML and LSCs but minimally expressed on normal HSPCs or other tissues for standalone or combinatorial targeting, and defining antigen-enriched genomic subgroups for biomarker-guided patient selection.

We therefore used high-dimensional single-cell proteomics to map the expression and co-expression of established and candidate surface antigens across LSC-enriched, progenitor, and differentiated AML compartments and assess genomic enrichment. Using a 51-marker CyTOF panel, we analyzed 95 specimens: 56 AML, 16 CMML, 5 MDS, and 18 healthy bone marrow or cord blood controls. The AML cohort was high risk: 52/56 (92.9%) R/R and 38/56 (67.9%) ELN 2022 adverse risk. Among evaluable cases, the most frequent mutations involved TET2, CEBPA, RUNX1, FLT3-ITD, and TP53 in AML and TET2, RAS, and ASXL1 in CMML. This analysis prioritized 5T4 for detailed characterization. 5T4 is an oncofetal surface glycoprotein encoded by TPBG. Using a validated anti-5T4 CyTOF antibody, we characterized expression across genetically and phenotypically diverse AML, CMML, and MDS cases. 5T4 expression varied markedly among and within patients, ranging from restricted subclonal expression to near-uniform leukemic-cell positivity in a distinct subset. In contrast, 5T4 was undetectable in cord blood and confined to a small fraction of healthy bone marrow cells at substantially lower antigen density than in leukemic samples, supporting a potential therapeutic window. Within CD34+ blasts, 5T4 was detected in approximately half of AML, CMML, and MDS cases. Mean 5T4 positivity in LSC-enriched compartments was 77.3% ± 23.3% in CMML and 82.8% ± 25.2% in MDS, with broad expression also observed in AML LSC-enriched populations. 5T4 also remained detectable in differentiated CD34-negative/CD33-positive blasts, demonstrating coverage across leukemic differentiation states. Together, its expression across LSC-enriched and differentiated leukemic compartments, with limited normal hematopoietic expression, supported therapeutic development.

We therefore advanced 5T4 from expression analysis  to therapeutic development. Accordingly, 5T4-Fc immunization yielded 88 hybridoma clones, including 32 antigen-specific binders and top five recombinant leads.  Iterative screening identified clone 34 as the strongest binder across tested cell lines in both hybridoma-derived and recombinant formats. scFvs from lead clones 34, 65, and 123 were incorporated into second-generation CD28/CD3ζ CARs. Clones 34 and 123 mediated the greatest cytotoxicity against 5T4-positive THP-1 and Kasumi-1 cells. CyTOF profiling after target coculture confirmed the same functional hierarchy: clone 34 showed the strongest induction of pS6, AKT/mTOR-associated signaling, and activation, proliferation, and cytotoxic effector markers, followed by clone 123. In Raji-5T4 xenografts, the lead construct, clone 34, achieved complete tumor clearance, with all treated mice remaining alive through day 85; the second-ranked construct, clone 123, extended median survival to 48 days versus 19 days in controls. In THP-1 xenografts, clones 34 and 123 approximately doubled median survival relative to controls (75 and 70 versus 35 days) and markedly reduced leukemia burden by day 28. Clone 65 showed only modest activity in both models. Exploratory genomic-proteomic analyses identified additional genotype-antigen associations; independent-cohort validation is ongoing, and updated findings will be presented.

5T4 is a therapeutically actionable myeloid malignancy-associated antigen spanning LSC-enriched and differentiated leukemic compartments with limited expression in normal hematopoiesis. Iterative optimization yielded clone 34, a lead CAR construct with potent cytotoxicity and durable activity across complementary xenograft models, supporting further translational development of 5T4-directed immunotherapy.

 

Muharrem Muftuoglu, MD: SELLAS Life Sciences Group - Research Funding; Senti Biosciences - Research Funding